TONIX PHARMACEUTICALS, INC. – Trademark Portfolio
Entity Type: 03
TONIX PHARMACEUTICALS, INC. holds 30 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 29 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 2 trademarks are registered and 6 are pending. Notable registered marks include TONMYA and TONIX PHARMACEUTICALS. The owner is based in New York, NY.
509 Madison Avenue, Suite 306
New York, NY 10022
Showing of trademarks Trademarks
Trademark Classifications
TONIX PHARMACEUTICALS, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does TONIX PHARMACEUTICALS, INC. have?
TONIX PHARMACEUTICALS, INC. has 30 U.S. trademarks filed with the USPTO. Of these, 2 registered, 6 pending, 21 abandoned, 1 cancelled.
What trademark classes does TONIX PHARMACEUTICALS, INC. file in?
TONIX PHARMACEUTICALS, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are TONIX PHARMACEUTICALS, INC.'s most well-known trademarks?
TONIX PHARMACEUTICALS, INC.'s registered trademark portfolio includes well-known marks such as TONMYA and TONIX PHARMACEUTICALS. These are among 2 currently registered trademarks in the portfolio.
What is TONIX PHARMACEUTICALS, INC.'s trademark registration success rate?
TONIX PHARMACEUTICALS, INC. has a 8% trademark registration rate, with 2 out of 24 resolved applications resulting in successful registration. Currently, 6 applications are pending review.